Edgewise reports positive Phase 1 MAD results for EDG-5506; Phase 2 in BMD and DMD planned for 2022

Edgewise Therapeutics, Inc.

EDG-5506 generally well tolerated; no serious adverse events; mild dizziness/somnolence resolved.
PK data showed muscle concentrations well above efficacious levels from preclinical DMD models.
PD demonstrated dose-proportional inhibition of involuntary twitch without affecting voluntary strength or cardiac myosin.
Phase 1b dosing of BMD patients initiated; Phase 2 in BMD expected Q1 2022, DMD H2 2022.
Follow-on open-label study in BMD planned for Q1 2022 to assess biomarkers over 3 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.